Given the important role of the PI3K/Akt/mTOR signaling pathway in cancer, it has been reported that CMG002, a PI3K/mTOR dual-target inhibitor, overcomes chemoresistance in ovarian cancer (21). This evidence concerns the gene AKT1 and cancer.